Press Releases
Cambridge Healthtech Institute Announces its 14th Annual Structure-Based Drug Design Event
NEEDHAM, MA - Feb 27, 2014 - Cambridge Healthtech Institute
(CHI) today announced the final agenda for its 14th AnnualStructure-Based Drug Design conference to be held
on May 21-22, 2014 at the Westin Boston Waterfront, Boston,
Massachusetts. The conference will showcase informative,
high-quality case studies, innovative techniques, and strategies to
move from computation to experiment, and finally, to drug.
Top scientists from pharma and biotech will address how they are
hitting epigenetic targets, provide updates on the newest wave of
GPCRs and other membrane proteins, and discuss the latest in
fragment-based drug design. Attendees will return to their
organizations with fresh perspectives and new ideas to maximize
productivity and increase successes in drug discovery.
Keynote Presentation:
-- Structures, Chemical Probes, New Biology, New Targets for Drug
Discovery: Is This the Right Sequence?
Chas Bountra, Ph.D., Head, Structural Genomics Consortium (SGC);
Professor, Translational Medicine; Associate Head, Medical
Sciences, University of Oxford
Sessions:
-- Updates on New Compounds and Targets
-- Properties of Fragments
-- GPCRs and Other Membrane Proteins
-- Water in Drug Design
-- Innovative Approaches to Enable Discovery
In addition, a pre-conference dinner short course on "Structure-
and Dynamics-Based Design Strategies," will be hosted by Steven
LaPlante, Ph.D., Founder & CEO, NMX Research & Solutions;
Adjunct Professor, Institut National de la Recherche Scientifique
(INRS) on Tuesday, May 20 from 6:00-9:00 pm. Plus, an
exhibit/poster hall will stimulate dialogue for solutions most
relevant to structure-based drug design.
"For this year's event, we really took attendee feedback into
account to give the conference a bit of a face-lift. The program
will feature all new content and expanded coverage on the topics
that matter most to industry researchers, and the presentations are
going to give attendees actionable advice to take to their labs. I
think the discussions generated here will be some of the best yet,"
said Samantha Lewis, Conference Producer, CHI.
The conference is once again endorsed by the International Society
for Computational Biology (ISCB) as a sponsoring society and Bio-IT
World as the official media sponsor.
Past attendees of this conference had this to say about their
experience at the meeting:
"The selection and speakers and presentations strongly demonstrated
the expansive breadth and impact of structure-based drug design." -
- Director of Bioinformatics, ActivX Biosciences
"Some very important principles were highlighted and the best thing
was that the speakers could demonstrate working solutions." --
Computational Chemist, Bayer HealthCare
"Good quality, up-to-date presentations made this a stimulating and
informative conference." -- CSO, De Novo Pharmaceuticals Ltd.
Important Dates:
Poster abstract submission deadline: April 4, 2014
Advanced registration discount deadline: April 18, 2014
For additional information, visit www.healthtech.com/structure-based-drug-design
or call CHI at 781-972-5400.
Writers and editors are invited to attend. To request a press pass,
email Lisa Scimemi, lscimemi@healthtech.com.
About Cambridge Healthtech Institute (CHI):
Cambridge Healthtech Institute (CHI), founded in 1992, is the
industry leader in providing superior quality scientific
information to eminent researchers and business experts from top
pharmaceutical, biotech, and academic organizations. Delivering an
assortment of resources such as events, reports, publications and
eNewsletters, CHI's portfolio of products include Cambridge
Healthtech Institute Conferences, Barnett International, Insight
Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting
Planners, and Cambridge Healthtech Media Group. For more
information, visit www.chicorporate.com.
